The bizzare phenomenon of smokers’ paradox in the immediate outcome post acute myocardial infarction: an insight into the Malaysian National Cardiovascular Database-Acute Coronary Syndrome (NCVD-ACS) registry year 2006–2013 by unknown
Venkatason et al. SpringerPlus  (2016) 5:534 
DOI 10.1186/s40064-016-2188-3
RESEARCH
The bizzare phenomenon of smokers’ 
paradox in the immediate outcome post 
acute myocardial infarction: an insight 
into the Malaysian National Cardiovascular 
Database-Acute Coronary Syndrome 
(NCVD-ACS) registry year 2006–2013
Padmaa Venkatason1, Norsabihin Mohd Salleh1, Yong Zubairi2, Imran Hafidz1, Wan Azman Wan Ahmad1, 
Sim Kui Han3 and Ahmad Syadi Mahmood Zuhdi1*
Abstract 
Background: ‘Smoker’s paradox’ is a controversial phenomenon of an unexpected favourable outcome of smokers 
post acute myocardial infarction. There are conflicting evidences from the literature so far. We investigate for the exist-
ence of this phenomenon in our post acute myocardial infarction patients.
Methods:  We analysed 12,442 active smokers and 10,666 never-smokers diagnosed with STEMI and NSTEMI from 
the Malaysian National Cardiovascular Database-Acute Coronary Syndrome (NCVD-ACS) year 2006–2013 from 18 
hospitals across Malaysia. Comparisons in the baseline characteristics, clinical presentation, in-hospital treatment and 
short term clinical outcome were made between the two groups. To compare the clinical outcome, an extensive 
multivariate adjustment was made to estimate the allcause mortality risk ratios for both groups.
Results: The active smokers were younger (smokers 53.7 years vs non-smokers 62.3 years P < 0.001) and had lower 
cardiovascular risk burden and other co-morbidities. STEMI is more common in smokers and intravenous thrombolysis 
was the main reperfusion therapy in both groups. Smokers had a higher rate of in-hsopital coronary revascularisation 
in NSTEMI group (21.6 % smokers vs 16.7 % non-smokers P < 0.001) but similar to non-smokers in the STEMI group. 
Multivariate adjusted mortality risk ratios showed significantly lower mortality risks of smokers at both in-hospital (RR 
0.510 [95 % CI 0.442–0.613]) and 30-day post discharge (RR 0.534 [95 % CI 0.437–0.621]).
Conclusion: Smoking seems to be associated with a favourable outcome post myocardial infarction. The phenom-
enon of ‘smoker’s paradox’ is in fact a reality in our patients population. The definitive explanation for this unexpected 
protective effect of smoking remains unclear.
© 2016 Venkatason et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Smoking is a well established risk factor for cardiovascu-
lar disease (Chen and Boreham 2002). ‘Smoker’s paradox’ 
is, however, an observational phenomenon of an unex-
pected favourable outcome in smokers post acute myo-
cardial infarction (MI). There has been great interest in 
this controversy over the past decades. Some suggest that 
the paradoxical favourable outcome is due to the more 
‘thrombotic’ nature of MI in smokers as oppose to ath-
erosclerotic in non-smokers and hence better reperfusion 
response after thrombolyis (Grines et  al. 1995; Zahger 
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et al. 1995). Others argue that smokers were younger at 
the onset with better baseline prognostic factors such as 
lower rate of diabetes and hypertension among others 
(Weisz et al. 2005; Kelly et al. 1985). Nevertheless there is 
no universally accepted satisfactory explanation for this. 
Thus, we investigate for the existence of ‘smoker’s para-
dox’ in our post-MI population by means of anonymous 
patients data from the Malaysian National Cradiovascu-
lar Database registry-Acute coronary syndrome (NCVD-
ACS) year 2006–2013.
Methods
Study subjects and data collection
The Malaysian National Cardiovascular Disease Data-
base-Acute Coronary Syndrome (NCVD-ACS) registry 
was used to identify patients from 17 hospitals across 
Malaysia admitted with ST-elevation MI (STEMI) and 
non-ST elevation MI (NSTEMI) from the year 2006 to 
2013. NVCD registry is a prospective registry sponsored 
by the Ministry of Health, Malaysia (MoH) and co-spon-
sored by the National Heart Association of Malaysia 
(NHAM). A total of 23,108 patients were identified for 
this study. Patients selected were either active smokers 
(n = 12,442) or non-smokers (n = 10,666). Active smok-
ers were defined as patients having regularly smoked 
tobacco products/product (includes cigarettes, cigars or 
pipes) one or more times per day or have smoked within 
the 30  days prior to the admission. Non-smokers were 
defined as patients who have never smoked for their 
entire lives. Baseline characteristics, clinical presentation, 
in-hospital treatment, procedural details and clinical out-
come at discharge and at 30 days post discharge. Record 
matching against the National Death Register, Malaysia 
was performed to verify the mortality status (alive or 
dead) of all study patients.
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation and median (IQR) if skewed. The differences 
between active smokers and non-smokers were ana-
lysed using t test or Wicoxon rank sum test (if skewed). 
Categorical variables were described as numbers (per-
centages), and differences were analysed using the Chi-
square test or the Fisher exact test. To hinder biases in 
the estimates and loss of power, missing data for explana-
tory variables were assumed to be missing at random. A 
generalized linear model with a log link, binomial distri-
bution, and a robust variance estimator was used to esti-
mate the risk ratios. The risk ratios represent the relative 
risk for mortality of the patients in non-smokers com-
pared to active smokers. Variables that were statistically 
significantly different (a 2-sided P value of less than 0.05) 
between active smokers and non-smokers, that were of 
clinical importance, and that had sufficient outcomes 
in the respective subcategories were adjusted for in the 
model. Statistical significance was considered if the P 
value was less than 0.05 and the 95 % confidence intervals 
of risk ratios excluded the value of 1. All analyses were 
conducted using SPSS statistical software (version 21, 
IBM SPSS Statistics, USA).
Ethics approval and consent
This NCVD registry study was approved by the Medical 
Review & Ethics Committee (MREC), MOH Malaysia in 
2007 (Approval Code: NMRR-07-20-250). MREC waived 
informed consent for NCVD.
Results
Patients baseline characteristics (Table 1)
Demographics (Table 1)
Active smokers were significantly younger (53.7 vs 62.3 
years P  <  0.001) with higher male to female dominancy 
(97.9 vs 53.6 % P < 0.001) and Malay racial group (59.9 vs 
45.7 % P < 0.001).
Cardiovascular risk factors and co‑morbidities (Table 1)
Active smokers showed a better cardiovascular risk factor 
profile with significantly lower rate of diabetes mellitus 
(29.7 vs 52.8 % P < 0.001), hypertension (42.3 vs 69.3 % 
P < 0.001) and dyslipidaemia (23.6 vs 36.0 % P < 0.001). 
However the active smokers have higher rate of family 
history of premature coronary artery disease (CAD) (12.8 
vs 9.9 % P < 0.001).
Other co-morbidities of previous cerebrovascular dis-
ease, congestive cardiac failure, chronic renal failure, 
chronic lung disease and peripheral vascular disease were 
also significantly lower in the active smoking group.
ACS presentation and killip class (Table 1)
There is a significantly higher rate of STEMI in active 
smokers compared to the non-smokers (77.2 vs 53.3  % 
P  <  0.001). Within STEMI patients, the smokers had 
more patients who presented without clinical evidence of 
LV dysfunction (Killip 1) (66.1 vs 61.9 % P < 0.001).
In‑hospital acute treatment, coronary revascularisation 
and evedence‑based pharmacotherapy (Table 2)
Acute reperfusion therapy (Table 2)
Majority of the STEMI patients received IV thromboly-
sis (smokers 77.1 % vs non-smokers 69.0 %) with only a 
small minority had primary PCI done (smokers 9.5 % vs 
non-smokers 11.3  %). The median door to needle time 
was significantly shorter in the smokers’ group (smokers 
45 min vs non smokers 50 min).
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In‑hospital coronary angiogram/angioplasty 
and pharmacotherapy (Table 2)
In the STEMI group, the smokers received similar rate of 
invasive coronary revascularisation (29.8  % smokers vs 
29.2 % non-smokers). However in NSTEMI, the invasive 
revascularisatio rate is significantly higher in smokers 
(21.6 % smokers vs 16.7 % non-smokers). In terms of the 
evidence-based pharmacotherapy, more active smokers 
received aspirin (93.8 % smokers vs 87.9 % non-smokers) 
and statin (90.5 % smokers vs 86.3 % non-smokers) com-
pared to the non-smokers. The rate of other medications 
were the same for both groups.
Clinical outcome (all‑cause mortality) (Tables 3 and 4)
In‑hospital all‑cause mortality (Table 3)
The in-hospital mortality rates for STEMI, NSTEMI 
and overall groups were all consistently lower in active 
smokers compared to the non smokers. Despite exten-
sive multi-variate adjustments of all confounding fac-
tors, the mortality risk ratios remained significantly lower 
in smokers across all groups. STEMI RR 0.628 [95  % 
CI 0.586–0.673] P < 0.001, NSTEMI RR 0.423 [95 % CI 
0.369–0.575] P value <0.001, and overall RR 0.510 [95 % 
CI 0.442–0.613] P < 0.001.
30‑day post discharge all‑cause mortality (Table 4)
The mortality rate and the unadjusted mortality risk 
ratios remained lower in the active smokers at 30-day 
post discharge within all groups (STEMI, NSTEMI and 
overall). Again, even after extensive confounding multi-
variate risk adjustments, the risk ratios for active smokers 
were found to be significantly lower than non-smokers 
across all groups. STEMI RR 0.635 [95 % CI 0.592–0.681] 
P value <0.001, NSTEMI RR 0.489 [95 % CI 0.421–0.589] 
P value <0.001 and Overall RR 0.534 [95  % CI 0.437–
0.621] P value <0.001.
Discussion
Our population has high prevalence of smoking. Accord-
ing to the National Health and Morbidity Survey (NHMS) 
Malaysia, the prevalence of adult male smokers in Malay-
sian population is 46.5  %, highest among the Malays 
(55.9  %), lower education group and rural areas (Lim 
et  al. 2013). Reports from other regions regarding the 
unexpected favourable outcome of smokers post myocar-
dial infarction has dated back to the pre-thrombolytic era 
of STEMI (Kelly et  al. 1985; Helmers 1973). There have 
been great debates in the literature on this controversial 
topic and it has oftenly been disputed mainly on the con-
founding age and pre-morbid differences which favour 
smokers than the non-smokers in general (Grines et  al. 
1995; Barbash et al. 1995; Zuhdi et al. 2013).
Nevertheless, the main pathogenesis of acute myo-
cardial infarction in smokers has been reported to dif-
fer from those of non-smokers. There is documented 
increase in haematocrit and fribrinogen levels in smokers 
which predispose them more to intra-coronary throm-
bosis (Sambola et al. 2003). It is thus suggested that the 
coronary flow limitation is largely due to thrombogenic 
obstruction with minimal underlying atherosclerotic 
narrowing. Where as, in non-smokers it is the ath-
erosclerotic narrowing which is predominant (Grines 
Table 1 Patients’ baseline characteristics
STEMI ST elevation myocardial infarction, NSTEMI non-ST elevation myocardial 
infarction








 Mean 53.7 (53.46, 53.83) 62.3 (62.09, 62.45) <0.001*




 Male 12182 (97.9 %) 5712 (53.6 %) <0.001
 Female 260 (2.1 %) 4954 (46.4 %)
Ethnicity
 Malay 7398 (59.5 %) 4879 (45.7 %)
 Chinese 2173 (17.5 %) 2409 (22.6 %) <0.001
 Indian 1920 (15.4 %) 2755 (25.8 %)
 Others 951 (7.6 %) 623 (5.8 %)
Risk factors/co-morbidities
 Dyslipidaemia 2933 (23.6 %) 3838 (36.0 %) <0.001
 Hypertension 5267 (42.3 %) 7390 (69.3 %) <0.001
 Diabetes 3691 (29.7 %) 5627 (52.8 %) <0.001
 Family history 
premature CAD
1595 (12.8 %) 1051 (9.9 %) <0.001
 Cerebrovascular 
disease
228 (1.8 %) 469 (4.4 %) <0.001
 Peripheral  
vascular disease
43 (0.3 %) 97 (0.9 %) <0.001
 Chronic lung 
disease
276 (2.2 %) 264 (2.5 %) <0.001
 Congestive heart 
failure
416 (3.3 %) 885 (8.3 %) <0.001
 Chronic renal 
failure
311 (2.5 %) 1028 (9.6 %) <0.001
ACS diagnosis
 STEMI 9609 (77.2 %) 5684 (53.3 %) <0.001
 NSTEMI 2833 (22.8 %) 4982 (46.7 %)
Killip class
 Killip 1 6712 (66.1 %) 5092 (61.9 %)
 Killip 2 2081 (20.5 %) 1951 (23.7 %) <0.001
 Killip 3 429 (4.2 %) 515 (6.3 %)
 Killip 4 939 (9.2 %) 672 (8.2 %)
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et al. 1995; Zahger et al. 1995). With this came the the-
ory of fibrin-rich thrombus in smokers which is said to 
be more susceptible to thrombolysis/anti-coagulation 
and theoretically leads to the seemingly better outcome 
of smokers particularly in the thrombolytic era (Aune 
et  al. 2011). Some other hypotheses include higher 
case-fatality among smokers even before reaching the 
hospitals (Sonke et  al. 1997) and the ischaemic precon-
ditioning effect of tobacco (Gupta et al. 2014). However, 
these remain as theories without sufficient data for defin-
itive proof to relate them to the favourable clinical out-
come of smokers.
In one study, the response in myocardial reperfusion 
after thrombolytic therapy in smokers were objectively 
assessed and compared to non-smokers in a study using 
TIMI myocardial perfusion grade (TMPG) which showed 
better response in smokers (Kirtane et al. 2005). However 
more recent data in the era of primary PCI showed no sig-
nificant difference betweeen smokers and non-smokers (De 
Luca et al. 2014; Allahwala et al. 2013) and smokers benefit 
equally from PCI and thrombolysis (Rasmussen et al. 2012).
Our study was done in the background of IV throm-
bolysis as the dominant reperfusion strategy for STEMI. 
Only a small minority (<10  %) of STEMIs underwent 
Table 2 In-hospital acute treatment, coronary revascularisation and evidence-based pharmacotherapy
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ADP adenosine diphosphate
All P values are calculated using the Chi-square test unless stated
* Wicoxon rank sum test
Active smokers Non‑smokers P value
Thrombolysis
 Given 7239 (77.1 %) 3826 (69.0 %) <0.001
 Not given—proceeded to primary angioplasty 891 (9.5 %) 627 (11.3 %)
 Not given—missed 961 (10.2 %) 807 (14.6 %)
 Not given—patient refusal 34 (0.4 %) 20 (0.4 %)
 Not given—contraindicated 269 (2.9 %) 252 (4.5 %)
Door to needle time (median) 45 (26–82) 50 (30–94) <0.001*
STEMI
Percutaneous coronary intervention 2679 (29.8 %) 1541 (29.2 %) <0.001
NSTEMI
Percutaneous coronary intervention 566 (21.6 %) 773 (16.7 %) <0.001
Evidence-based Medications
 Aspirin 10,445 (93.8 %) 8370 (87.9 %) <0.001
 ADP-antagonist 6629 (78.4 %) 5462 (73.0 %) <0.001
 ACE-I/ARB 6575 (53.4 %) 5422 (52.3 %) 0.080
 Beta blocker 7301 (68.4 %) 6350 (68.2 %) 0.761
 Statin 10,024 (90.5 %) 8179 (86.3 %) <0.001
Table 3 Non-adjusted and adjusted in-hospital mortality risk ratios of active smokers and non-smokers
* Risk ratios were adjusted with respect to each variable with significant P value (<0.05) in the univariate analysis (refer Tables 1, 2)
ACS type Number of  
patients
Deaths, n (%) Unadjusted  
risk ratio (95 % CI)
P value Adjusted risk  
ratio (95 % CI)
P value
All (n = 23,108)
 Active smokers 12,442 699 (5.6 %) 0.330 (0.311, 0.350) <0.001 0.510 (0.442, 0.613)* <0.001
 Non-smokers 10,666 1026 (9.6 %) 1 1
STEMI (n = 15,293)
 Active smokers 9609 566 (5.9 %) 0.358 (0.293, 0.436) <0.001 0.628 (0.586, 0.673)* <0.001
 Non smokers 5684 645 (11.3 %) 1 1
NSTEMI (n = 7815)
 Active smokers 2833 133 (4.7 %) 0.328 (0.309, 0.348) <0.001 0.423 (0.369, 0.575)* <0.001
 Non smokers 4982 381 (7.6 %) 1 1
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primary PCI and overall in-hospital coronary revascu-
larisation was around 30 %. The NSTEMI patients were 
treated mainly with non-invasive pharmacotherapy with 
only around 20  % received in hospital coronary revas-
cularisation. After extensive covariates adjustments, 
we observed that active smokers had a (overall) sig-
nificantly lower in-hospital mortality risk compared to 
those who never smoked. Sub-group analysis of STEMI 
and NSTEMI were both consistent with a lower adjusted 
mortality risk compared to non-smokers. At 30-day post 
discharge, the trend in lower adjusted mortality risks 
were sustained across all groups with smokers maintain-
ing the protective effect.
However this study only looked at the immediate clini-
cal outcome (in-hospital and 30-day post discharge). 
Patients’ smoking status after the myocardial infarc-
tion was not assessed and hence the sustainability of 
the favourable effect of smoking in the long run for our 
patients remains unknown. Some recent data showed 
that smoking is actually related to increased long term 
mortality (Robertson et al. 2014; Takagi et al. 2014) and 
quitting smoking is associated with improved survival 
after acute coronary syndromes (Gerber et  al. 2009; 
Chow et  al. 2010). This comes as the suggestion that 
cigarette smoking may increase platelet aggregation in 
patients with ischemic heart disease in an aspirin non-
responsive manner (Pamukcu et al. 2011). All these data 
suggests that favourable smokers’ paradox effect is only 
limitted to short term outcome if it does exist at all.
The observed phenomenon of smokers’ paradox is 
thus a highly controversial one. Many other studies have 
refuted the existence of this phenomenon (Andrikopou-
los et al. 2001; Gottlieb et al. 1996). A study showed that 
smokers had better early outcome but the benefit rapidly 
vanishes in the late phase (Takagi et al. 2014) and in the 
event of post coronary revascularisation (PCI or CABG), 
smoking is associated with adverse outcome (Zhang et al. 
2015; Yi-Hwei et al. 2013).
Collectively, current data suggests that even though 
smoking may be associated with a favourable early out-
come, the overall picture is still not in favour of smok-
ing especially on long term outcome and post coronary 
revascularisation. This study did not assess the smok-
ing status post myocardial infarction and based on the 
above evidence from the literature, the favourable out-
come of smokers are short-lived and hence we con-
tinue to strongly advocate the importance of smoking 
cessation.
Conclusion
The phenomenon of ‘smoker’s paradox’ is in fact a real-
ity among our patients and is unlikely due to just plain 
bias from the favourable baseline characteristics of smok-
ers. Even after extensive covariates adjustment for all the 
favourable baseline characteristics in active smokers, 
the reduction in mortality risks persists. In conclusion, 
‘smoker’s paradox’ in the immediate outcome post myo-
cardial infarction was observed in our patients’ popula-
tion. Active smokers tend to do better at both in-hospital 
and 30-days post discharge with significantly lower over-
all mortality risk compared to those patients who never 
smoked. The real explanation to this bizarre outcome 
however, remains unclear.
Nevertheless the study is limitted to only immediate 
outcome. Smoking status post moyocardial infarction 
and its effect on long term outcome was not assesed. 
Currently, the overall evidence from the literature is still 
in favour of non-smokers especially for long term out-
come and post coronary revascularisations.
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